相关实验视频
Updated: Jul 12, 2025

05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.2K
免疫相关基因在动脉样硬化的发病过程中:基于性别差异
Peng Zhang1, Hui Lin1, Yan Guo2
1Department of Cardiology, Shaoxing People's Hospital, Shaoxing, Zhejiang, 312000, People's Republic of China.
Journal of inflammation research
|October 24, 2023
概括
这项研究确定了在男性动脉样硬化中过度表达的七种免疫相关基因 (IRG),揭示了两性之间免疫细胞透的显著差异. 这些发现表明,有潜在的性别特异性动脉样硬化治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 动脉样硬化是一个全球性的健康挑战,死亡率高.
- 性别显著影响动脉样硬化进展,但遗传和免疫细胞差异仍然未得到充分研究.
研究的目的:
- 为了调查男性和女性动脉样之间的遗传和免疫细胞差异.
- 为了确定与动脉样硬化相关的性别特异性免疫相关基因 (IRG).
主要方法:
- 对GSE43292数据集的差异基因表达分析.
- 对已识别的IRG进行基因本体学 (GO) 和KEGG通路丰富分析.
- 蛋白与蛋白相互作用 (PPI) 网络构建和免疫细胞透分析 (ssGSEA).
- 使用GSE28829数据集和动脉样硬化小鼠模型进行验证.
主要成果:
- 七个IRG (CCL13,IL1RN,FPR2,S100A8,CCL19,CXCL1,CXCL8) 在男性动脉样硬化中过度表达.
- 丰富分析突出了炎症和细胞因子介导的途径.
- 与女性相比,男性标本的免疫细胞透率显著更高.
- 确定的IRG在验证数据集和动物模型中显示出高的诊断价值.
结论:
- 七个IRG强调了动脉样硬化,特别是男性免疫细胞透的显著性别差异.
- 这些发现为开发针对动脉样硬化的个性化,性别特定的治疗策略提供了洞察力.
相关概念视频
Coronary Artery Disease I: Introduction
17
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
17
Atherosclerosis I: Introduction
9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
11
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
11
Psychoneuroimmunology: Cardiovascular Disease
33
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
33
Coronary Artery Disease II: Pathophysiology
12
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
12
Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11

